National and international fertility organizations scaled operations through acquisitions, AI partnerships, and patient access initiatives
The fertility clinic network landscape continued evolving rapidly through the first half of 2026 as organizations invested heavily in expansion, operational infrastructure, AI-enabled reproductive technologies, and patient affordability initiatives. Across North America and Europe, fertility groups pursued acquisitions, opened new clinic locations, expanded laboratory capabilities, and strengthened physician recruitment efforts amid sustained demand for fertility care services.
Many organizations also increased visibility through research presentations, strategic partnerships, and national rankings. AI-assisted embryo selection, predictive analytics, digital patient platforms, and affordability-focused partnerships emerged as recurring themes across the sector, while consolidation activity continued reshaping the competitive landscape. The following summaries highlight major developments among several leading fertility clinic networks and organizations operating across the fertility and reproductive health industry.
CCRM Fertility
In April 2026, CCRM expanded access in the Southeast through the launch of CCRM Fertility of Greenville, South Carolina. Public materials surrounding the opening emphasized inclusive family-building services and expanded fertility access for patients across the region.
The organization additionally maintained strong national visibility through rankings and technology-focused initiatives. In April 2026, seven CCRM clinics were recognized in Newsweek’s “America’s Best Fertility Clinics 2026” rankings, including locations in Colorado, New York City, Boston, San Francisco, Houston, Scottsdale, and Minneapolis.
CCRM also appeared in broader industry discussions surrounding AI-assisted reproductive medicine. In May 2026, a New York Post feature on “AutoIVF” technology quoted CCRM New York’s Dr. Brian Levine discussing AI-assisted fertilization systems designed to automate portions of egg identification and fertilization workflows within IVF labs. Separately, the organization launched a clinical study focused on In Vitro Maturation (IVM) treatment as a lower hormone alternative to traditional IVF cycles.
FutureLife Group
FutureLife Group continued aggressive international expansion throughout late 2025 and early 2026 as the organization expanded its pan-European fertility platform. In December 2025, FutureLife announced a partnership with Ethmar International Holding to launch Institut Marquès Abu Dhabi, bringing a European reproductive medicine brand into the UAE market ahead of a planned 2026 opening.
The organization also significantly increased operational scale through the acquisition of the Bahçeçi Group, adding fertility clinics across Turkey, Kosovo, Bulgaria, and Bosnia & Herzegovina. Public reporting stated the transaction increased FutureLife’s annual IVF cycle volume to more than 74,000 cycles annually.
In 2025, FutureLife further expanded its Southern European footprint through the acquisition of Milano Fertility Clinic in Italy. The organization also strengthened its Eastern European presence through the acquisition of Atentica Fertility Clinic in Iași, Romania, adding the first fertility center in eastern Romania to its network.
In May 2026, FutureLife also expanded its investment in AI-enabled reproductive medicine through a partnership with Alife Health. Public reporting surrounding the initiative described predictive analytics and large-scale IVF cycle data as tools intended to support more personalized treatment planning and clinical decision-making across portions of the organization’s European fertility network.
Innovation Fertility
Kyle Francis has now been the CEO of Innovation Fertility for two years. His experience spans fertility care, healthcare finance, M&A, and business development. He has held leadership roles including CFO and Chief Business Development Officer at Spring Fertility, CEO and CFO of Southern California Reproductive Center, and executive positions tied to American Oncology Network and Apollo Medical Holdings. His background also includes investment banking, healthcare advisory work, and board leadership in technology and healthcare companies.
Public-facing messaging throughout 2026 positioned Innovation Fertility’s AI-supported workflows as tools designed to improve outcome prediction, optimize treatment planning, and support clinical decision-making across its growing fertility network.
INVO Fertility Expands Through Progyny Access, Acquires Indiana clinic
INVO Fertility continued advancing its clinic-ownership and INVOcell commercialization strategy through late 2025 and the first half of 2026, with recent developments spanning payer access, clinic network expansion, financial performance, and intellectual property.
In March 2026, INVO Fertility’s Wisconsin Fertility Institute joined the Progyny network, making the clinic in-network for eligible Progyny members. The announcement described Progyny as providing fertility and family-building benefits to approximately 7.2 million covered lives through more than 600 employers and plan sponsors nationwide, expanding Wisconsin Fertility Institute’s access to employer-sponsored patients across Wisconsin and surrounding regions.
INVO also expanded its clinic footprint through acquisition activity. In December 2025, the company signed a definitive purchase agreement to acquire Family Beginnings, P.C., an Indiana-based fertility clinic, and in February 2026, INVO closed the acquisition of Family Beginnings. The transaction added a fourth operational fertility clinic to INVO’s U.S. network and expanded the company’s Midwest presence. INVO reported that Family Beginnings generated approximately $1.2 million in trailing twelve-month revenue and approximately $0.2 million in net income for the period ended September 30, 2025.
The company’s financial disclosures also reflected its shift toward a clinic-operations model. In its fiscal year 2025 Form 10-K, INVO reported total revenue of approximately $6.84 million, including approximately $6.72 million in clinic revenue. In a February 2026 shareholder letter, INVO highlighted strengthened fundamentals, recent financing activity, Family Beginnings, and its clinic-plus-INVOcell growth strategy, emphasizing a model that combines owned fertility clinics with continued distribution of the company’s INVOcell technology.
Technology and product developments further supported that strategy. In October 2025, INVO partnered with Heidi Health to bring AI-powered clinical scribe tools to Wisconsin Fertility Institute, aiming to reduce documentation burden and support clinic workflow efficiency. In February 2026, INVO announced issuance of U.S. Patent No. 12,544,204 B2 for a modified INVOcell device, extending intellectual property protection for the device through 2040.
RMA
In March 2026, the organization also participated in a high-profile Costco and Sesame partnership designed to reduce fertility medication costs by as much as 80% while improving treatment access for patients across the United States.
Under the model, patients begin with Sesame clinicians for consultations, diagnostic coordination, and fertility workups. Patients requiring advanced reproductive care — including IVF, IUI, or egg freezing — are then referred into IVI RMA North America’s clinic network for specialty treatment.
The partnership drew significant attention primarily because of its medication pricing component. Costco Pharmacy offered fertility medications at discounts reportedly reaching up to 80%, with the companies stating that IVF medication costs could decline from typical self-pay ranges of roughly $3,000–$6,000 per cycle to approximately $1,640–$2,296 in some cases.
In October 2025, during ASRM 2025, IVI RMA North America reported presenting 36 studies and poster sessions spanning reproductive genetics, laboratory science, and IVF outcomes.
In April 2026, ten IVI RMA North America clinics were recognized in Newsweek’s “America’s Best Fertility Clinics 2026” rankings, including Boston IVF, RMA New York, RMA New Jersey, RMA Philadelphia, RMA Connecticut, RMA Northern California, RMA Southern California, RMA Michigan, Reproductive Science Center of the Bay Area, and TRIO Fertility. Rankings were based on accreditation data, patient satisfaction scores, clinical performance metrics, and physician reputation surveys.
Inception Fertility / The Prelude Network
Inception Fertility and The Prelude Network continued emphasizing physician collaboration, operational scale, and workforce development throughout late 2025 and 2026. In March 2026, the organization hosted the 2026 Inception Fertility Physician Summit in Orlando, Florida, bringing together clinicians, researchers, and fertility leaders from across the Prelude Network.
Public materials surrounding the summit emphasized collaboration on clinical standards, workforce development, physician recruitment, and patient care innovation across affiliated clinics.
Prelude also continued expanding its national visibility through partnerships and patient access initiatives. Public-facing materials described a network of more than 90 fertility care locations offering IVF, egg freezing, preimplantation genetic testing (PGT), donor services, and LGBTQ+ family-building care. Additional visibility came through collaborations connected to CooperSurgical and fertility grant programs.
Leadership messaging throughout 2026 additionally highlighted embryologist staffing and reproductive endocrinologist recruitment as ongoing operational priorities amid continued nationwide fertility workforce shortages.
Pinnacle Fertility
Growth followed through the integration of Genesis Fertility in Brooklyn, New York, a practice with more than 40 years of operating history, and a partnership with Tulsa Fertility Center, expanding Pinnacle’s reach into the South Central United States.
The network additionally maintained national visibility through clinical rankings, with multiple Pinnacle-affiliated clinics appearing in Newsweek’s “America’s Best Fertility Clinics 2026” rankings.
In the top 50 fell Pinnacle’s locations in Seattle, Scottsdale, and suburban Detroit.
POPART: Physician Owned Practice Alliance for Reproductive Technologies
POPART: Physician Owned Practice Alliance for Reproductive Technologies continued representing a physician-owned collaborative model within the broader fertility industry landscape throughout 2026. The organization’s positioning within the fertility sector reflected continued industry interest in physician-led governance models and alternatives to private equity-backed consolidation.
As consolidation activity accelerated across reproductive healthcare, physician-owned alliance structures remained part of broader industry conversations surrounding clinical autonomy, operational independence, and long-term physician leadership within fertility practices. Public-facing materials from POPART continued emphasizing physician ownership and collaborative operational support among affiliated fertility practices.
Piedmont Reproductive Endocrinology Group (PREG)
Piedmont Reproductive Endocrinology Group (PREG) continued expanding operationally and clinically throughout 2026. In January 2026, the organization formally joined the US Fertility network, extending the physician-owned partnership’s footprint across the Southeastern United States. PREG brought six locations across the Carolinas into the network and added expertise in IVF, fertility preservation, egg donation, and third-party reproduction. PREG had already recruited two graduates from the REI Fellowship Class of 2025.
The Fertility Partners
The Fertility Partners continued focusing on operational growth and fertility access expansion throughout 2026. Leadership messaging emphasized continued investment in fertility care infrastructure, clinic expansion, and responding to declining national fertility rates and growing patient demand across Canada.
One of the organization’s most notable developments was the appointment of Heather Stark as CEO in January 2026, making her the first female chief executive in the organization’s history.
The organization also publicly discussed plans to increase treatment capacity while strengthening physician support infrastructure and operational scale throughout its clinic network.
Kindbody
Kindbody continued emphasizing technology integration, operational scale, and patient affordability initiatives throughout 2026.
In February 2026, Kindbody unveiled a next-generation fertility platform integrating AI-driven intelligence, unified patient support tools, and clinical workflow technology designed to improve outcomes while lowering treatment costs.
The organization also partnered with Luna wearable health technology to support biometric and data-driven fertility care initiatives combining wearable monitoring with fertility treatment insights.
Was Your Org Not Included?
Don't let your company miss out again.
Your company may have missed out on this coverage of your category before ESHRE, but Inside Reproductive Health overviews your category 4x per year.
Your competitors were covered because they are IVF Heroes Universe sponsors.
Don't miss out on the next coverage of your category--released before ASRM.
Over 60 leading fertility companies are leaders in the IVF Heroes Universe, isn't yours?
Year-long sponsorship is only $2,295 for the entire year, but get in now, before prices go up.